Cancer News

FDA Approves Keytruda for Adjuvant Treatment of Melanoma (03/04/2019)

On February 15, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA®, Merck) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. Approval was based on EORTC1325/KEYNOTE‑054 (NCT02362594), a randomized, double-blind, placebo-controlled, trial in 1019 patients with completely resected, stage IIIA (>1 mm lymph node metastasis), IIIB or IIIC... Continue Reading

Isatuximab – Promising for Treatment of Myeloma (02/25/2019)

A phase 3 comparative clinical trial evaluating Isatuximab has met the primary endpoint of delaying cancer progression in patients with relapsed/refractory multiple myeloma. Multiple myeloma is the second most common hematologic malignancy, with more than 138,000 new cases worldwide each year. Multiple myeloma remains incurable in the vast majority of patients, resulting in significant disease... Continue Reading

Keytruda Approved for Treatment of Stage III Melanoma (02/21/2019)

The U.S. Food and Drug Administration (FDA) has approved Keytruda for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete surgical resection. Adjuvant Therapy in Melanoma Melanoma is separated into five staging categories (stages 0-4).  Stage 3 melanoma is a cancer that has spread to the regional lymph nodes but... Continue Reading

TVEC-Genetically Modified Virus Injection into Tumor – A Valid Treatment for Metastatic Melanoma (01/25/2019)

Results published in the Journal of the American College of Surgeons show sustained effectiveness of disease response and favorable side effect profile. CHICAGO (January 25, 2019): Injection of a genetically modified virus that induces the body’s own immune cells to attack metastatic melanoma effectively treated almost 40 percent of patients with tumors that could not... Continue Reading

Targeted Combination Treatment for Melanoma now Available (09/10/2018)

The US Food and Drug Administration (FDA) approved the combination of Bratovi (encorafenib) and Mektovi (binimetinib)for use in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. About Braftovi + Mektovi (encorafenib) is an oral small molecule BRAF kinase inhibitor and Mektovi (binimetinib) is an oral small …

Continue reading "Targeted Combination Treatment for Melanoma now Available"

Melanoma Linked with CLL, Wilmot Recommends Close Monitoring (08/17/2018)

While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery — these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of skin cancer. Although a higher risk of melanoma had been known, a full analysis of detection …

Continue reading "Melanoma Linked with CLL, Wilmot Recommends Close Monitoring"

FDA Approves Tafinlar® + Mekinist® for Adjuvant Treatment of BRAF V600-mutant Stage III Melanoma (05/07/2018)

CancerConnect News: The US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.1 About Melanoma  Stage III melanoma includes cancers of any thickness that have spread to the …

Continue reading "FDA Approves Tafinlar® + Mekinist® for Adjuvant Treatment of BRAF V600-mutant Stage III Melanoma"

Tafinlar® + Mekinist® Demonstrates Long Term Survival Benefit for BRAF Mutation-Positive Metastatic Melanoma (04/05/2018)

CancerConnect News: Metastatic melanoma patients with the BRAF V600 mutation treated with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) can experience long term cancer free survival according to results presented at the 53rdAnnual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.1 About Melanoma  Metastatic melanoma refers to skin cancer that has spread from …

Continue reading "Tafinlar® + Mekinist® Demonstrates Long Term Survival Benefit for BRAF Mutation-Positive Metastatic Melanoma"

Keytruda Significantly Improved Recurrence-Free Survival in Patients with Stage 3 Melanoma (01/15/2018)

CancerConnect News:  The European Organisation for Research and Treatment of Cancer (EORTC), today announced that the phase 3 EORTC1325/KEYNOTE-054 trial investigating Keytruda (pembrolizumab), an anti-PD-1 precision immunotherapy for surgically resected high-risk melanoma, met the primary endpoint of improving recurrence-free survival. Adjuvant Therapy in Melanoma Melanoma is separated into five staging categories (stages 0-4).  Stage III …

Continue reading "Keytruda Significantly Improved Recurrence-Free Survival in Patients with Stage 3 Melanoma"

Combining T-VEC Herpes Virus With Keytruda Immunotherapy Shows Promise for Treating Advanced Melanoma (01/12/2018)

CancerConnect News: UCLA scientists have developed a potential new treatment for melanoma that has shown promising early clinical results.  In a two-year UCLA-led study, nearly two-thirds of people with advanced melanoma responded positively to a treatment that combines the immunotherapy drug keytruda (pembrolizumab) with a herpes virus called T-VEC (talimogene laherpareovec). Researchers found that the …

Continue reading "Combining T-VEC Herpes Virus With Keytruda Immunotherapy Shows Promise for Treating Advanced Melanoma"